Ardelyx Inc. (ARDX): BTIG Sees 172% Price Potential and Highlights Combined Peak Revenue Potential of $1.75 Billion!
Reading Time: 4 minutes
IBSRELA and XPHOZAH offer growth potential Ardelyx Inc. (ARDX) is a biotech company specializing in the development and marketing of therapies for gastrointestinal and cardiovascular diseases. Its pipeline includes IBSRELA and XPHOZAH (Tenapanor). IBSRELA is a medication for the treatment of irritable bowel syndrome with constipation (IBS-C). This is a condition where patients suffer from persistent constipation and abdominal pain. The drug acts directly in the intestine and alters how sodium is absorbed. This makes the stool softer, easing...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
